Anti-CD25 antibody (Daclizumab) maintenance therapy in pancreas transplantation

Transplantation Proceedings

Volumn 42, Issue 6, 2010, Pages 2003-2005

  Kirchner, V A ^a,b   Suszynski, T M ^a,b   Radosevich, D M ^b   Humar, A ^b   Dunn, T B ^b   Hill, M J ^b   Finger, E B ^b   Sutherland, D E R ^a,b   Kandaswamy, R ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; MAINTENANCE THERAPY; NEPHROTOXICITY; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; MIDDLE AGED; PANCREAS TRANSPLANTATION; REOPERATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77955530525     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.05.083     Document Type: Conference Paper

References (25)

1. R. Singh, and R. Stratta Advances in immunosuppression for pancreas transplantation Curr Opin Organ Transplant 13 2008 79
2. T. Baczkowska, and M. Durlik Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients Pol Arch Med Wewn 119 2009 318
3. S. Flechner, J. Kobashigawa, and G. Klintmalm Calcineurin inhibitorsparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity Clin Transplant 22 2008 1 15
4. I. Kaczmarek, D. Schmauss, and R. Sodian Late-onset tacrolimus-associated cerebellar atrophy in a heart transplant recipient J Heart Lung Transplant 26 2007 89
5. A. Ojo, P. Held, and F. Port Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931
6. H. Ekberg, H. Tedesco-Silva, and A. Demirbas SYMPHONY: comparing standard immunosuppression to low-dose cyclosporine, tacrolimus, or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation Am J Transplant 6 suppl 2 2006 83
7. J. Sageshima, G. Ciancio, and L. Chen Antiinterleukin-2 receptor antibodiesbasiliximab and daclizumabfor the prevention of acute rejection in renal transplantation Biologics 3 2009 319
8. D. Bruce, H. Sollinger, and A. Humar Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients Transplantation 72 2001 1637
9. F. Vincenti, R. Kirkman, and S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation N Engl J Med 338 1998 161
10. A. Webster, E. Playford, and G. Higgins Interleukin-2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials Transplantation 77 2004 166
11. M. Post, J. Raszeja-Wyszomirska, and K. Jarosz Immunosuppression with low-dose daclizumab in liver transplant recipients with impaired kidney function: a single-center experience Transplant Proc 2009 3107
12. A. Chaudhuri, O. Salvatierra, and M. Sarwal Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allograft Pediatr Transplant 13 2009 927
13. A. Sundberg, M. Rohr, and E. Hartmann Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients Clin Transplant 18 suppl 12 2004 61
14. B. Kaplan, P. West, and H. Neeley Case report: use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient Clin Transplant 22 2008 250
15. M. Sarwal, J. Vidhun, and S. Alexander Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation Transplantation 76 2003 1331
16. B. Nashan, S. Light, and I. Hardie Reduction of acute renal allograft rejection by daclizumab Transplantation 67 1999 110
17. R. Tesi, M. Henry, and E. Elkammas Predictors of long-term primary cadaveric renal transplant survival Clin Transplant 7 1993 345
18. A. Matas "Chronic rejection in renal transplant recipients: risk factors and correlates Clin Transplant 8 1994 332
19. G. Filler, I. Neuschulz, and I. Vollmer Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients Nephrol Dial Transplant 15 2000 867
20. K. Tamura, T. Fujimura, and T. Tsutsumi Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell Transplantation 59 1995 1606
21. Y. Hirano, S. Fujihura, and K. Ohara Mechanism of FK506-induced glucose intolerance in rats J Toxicol Sci 19 1994 61
22. A. Neto, E. Haapalainen, and R. Ferreira Metabolic and ultrastructural effects of cyclosporin A on pancreatic islets Transplant Int 12 1999 208
23. Y. Uchizono, M. Iwase, and U. Nakamura Tacrolimus impairment of insulin secretion in isolated rat islets occurs at multiple distal sites in stimulus-secretion coupling Endocrinology 145 2004 2264
24. J. Larsen, R. Bennett, and T. Burkman Tacrolimus and sirolimus cause insulin resistance in normal Sprague Dawley rats Transplantation 82 2006 466
25. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530